The in vivo administration of phosphorothioate antisense oligonucleotides targeting IGF-IR decreased receptor protein levels and concomitantly inactivated AKT and MAPK signaling pathways leading to C4HD BC growth inhibition [169]. This evidence concerns the gene IGF1R and breast cancer.